Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2022 ASCO Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following outcomes was reported at ASCO 2022 from the ENZAMET trial evaluating enzalutamide with androgen deprivation therapy (ADT) versus ADT with standard nonsteroidal anti-androgen therapy alone for patients with metastatic hormone-sensitive prostate cancer?

   a. A statistically significant improvement in overall survival with enzalutamide
   b. No statistically significant improvement in overall survival with enzalutamide

2. Which of the following conditions is an adverse event of special interest with enfortumab vedotin?

   a. Neuropathy
   b. Skin toxicity
   c. Hyperglycemia
   d. All of the above

3. Long-term follow-up data from the TheraP trial evaluating ^{177}Lu-PSMA-617 versus cabazitaxel for patients with metastatic castration-resistant prostate cancer who experienced disease progression after docetaxel demonstrated benefit with ^{177}Lu-PSMA-617 in which of the following endpoints?

   a. Overall survival only
   b. Progression-free survival only
   c. Both overall and progression-free survival
   d. Neither overall nor progression-free survival

4. Results presented at ASCO 2022 from the Phase III PROpel trial evaluating first-line olaparib with abiraterone for metastatic castration-resistant prostate cancer demonstrated benefit in comparison to placebo with abiraterone in which of the following endpoints?

   a. Overall survival only
   b. Radiographic progression-free survival (rPFS) only
   c. Both overall survival and rPFS
   d. Neither rPFS nor overall survival

5. Which of the following drug types best describes the mechanism of action of the novel agent belzutifan, which is being evaluated alone and in combination with pembrolizumab for clear cell renal cell carcinoma?

   a. MET inhibitor
   b. PARP inhibitor
   c. VEGFR inhibitor
   d. HIF-2-alpha inhibitor